证券代码：600211 证券简称：西藏药业 公告编号：2026-009 西藏诺迪康药业股份有限公司 关于回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/19，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 18 12 | 12 | 月 | 日~2026 | 年 | 月 | 日 17 | | 预计回购金额 | 17,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 4,000,058股 | | | | | | | | 累计已回购股数占总股本比例 | 1.24% | | | | ...

Group 1 - The first extraordinary general meeting of shareholders for 2026 was held on February 25, 2026, at the company's office in Chengdu, Sichuan Province [2] - The meeting was presided over by Chairman Chen Dabing, and the voting method complied with the Company Law and the Articles of Association [2] - All 9 current directors attended the meeting, including 3 independent directors, along with the company secretary and other senior executives [2] Group 2 - A resolution regarding the provision of guarantees by the company's controlling subsidiary was approved during the meeting [3] - The meeting's procedures, qualifications of the convener, attendees, and voting processes were confirmed to be in compliance with relevant laws and regulations [4] - The legal opinion from the witnessing law firm, Taihe Tai Law Firm, stated that the meeting's resolutions were legal and valid [4]

泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2026年第一次临时股东会的 泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2026年第一次临时股东会的法律意见书 2026年2月25日 中国·成都市天府新区隆和西巷 299 号 泰和泰中心 21-33F 21-33f, Tahota Center, No.299 Longhe West Lane, Tianfu New District, Chengdu, People's Republic of China 电话 | TEL: 86-28-8662 5656 www.tahota.com 致:西藏诺迪康药业股份有限公司 散启者 泰和泰律师事务所（以下简称"泰和泰"或"本所"）作为西藏 诺迪康药业股份有限公司(以下简称"西藏药业"或"公司")的常 年法律顾问,现接受公司的委托,指派谭蕾、陈科宇律师出席公司 2026 年第一次临时股东会,并依据《中华人民共和国公司法》(以下简称 "《公司法》"）《上市公司股东会规则》（以下简称"《股东会规 则》"）《西藏诺迪康药业股份有限公司章程》（以下简称"《公司 章程》"）及其他相关法律法规的规定,就公司本次股东会的召 ...

证券代码：600211 证券简称：西藏药业 公告编号：2026-008 西藏诺迪康药业股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 446 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 179,455,251 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 55.6762 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由董事长陈达彬先生主持，会议的表决方式符合《公司法》及《公司章程》 的规定。 (一) 股东会召开的时间：2026 年 2 月 25 日 (二) 股东会召开的地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五) 公司董事和董事会秘书的列席情况 1、公司在 ...

Investment Rating - The investment rating for the company is "Buy" [2][10] Core Insights - The company is a leading domestic specialized commercialization enterprise, and its innovative transformation has initiated a new growth cycle [5][18] - The company has excellent commercialization capabilities and a comprehensive research, production, and sales layout in the Southeast Asian market [6][20] - The company has four major business segments that are progressing in synergy, with stable contributions from cardiovascular and digestive health, and new growth momentum from skin health and ophthalmology [7][19] - The innovative pipeline is entering a harvest period, with multiple innovative products nearing commercialization [8][19] - The company has strong profitability and cash flow, providing a solid safety net for its innovative transformation and maintaining a stable high dividend policy [21] Summary by Sections 1. Company Overview - Founded in 1992, the company has evolved from a pharmaceutical agency to an innovative comprehensive pharmaceutical enterprise [22] - The company has a clear shareholding structure, with the actual controller being Mr. Lin Gang [28] - The negative impact of centralized procurement has been largely digested, with revenue and profit growth turning positive in the first half of 2025 [30] 2. Commercialization Capabilities - The company has a robust commercialization system, covering over 50,000 hospitals and 300,000 retail pharmacies, supported by a professional team of approximately 4,700 academic promoters [39] - The company has established a complete strategic layout in Southeast Asia, integrating research, registration, commercialization, and manufacturing [47] 3. Business Segments - The cardiovascular segment contributes approximately 48% of revenue, with the impact of centralized procurement clearing up and new products gaining traction [54] - The digestive and autoimmune segment accounts for about 30% of revenue, with stable growth from exclusive products and significant potential from innovative products [7] - The skin health segment, operated independently by a subsidiary, has high growth potential, with plans for a separate listing to reassess its value [7] - The ophthalmology segment contributes around 8% of revenue, with a competitive product portfolio including exclusive products and newly introduced drugs [7] 4. Innovative Pipeline - The company has nearly 40 innovative products in its pipeline, with six already commercialized and several others nearing NDA submission [8][19] - Key innovative products include Y-3 for acute ischemic stroke, Dexamethasone for chronic kidney disease, and ZUNVEYL for Alzheimer's disease, with peak sales potential exceeding 10 billion [8][19] 5. Financial Forecasts - Revenue projections for 2025-2027 are estimated at 82.16 billion, 98.59 billion, and 120.28 billion respectively, with year-on-year growth rates of 10%, 20%, and 22% [9] - Net profit forecasts for the same period are 16.15 billion, 18.50 billion, and 22.38 billion, with growth rates of 0%, 15%, and 21% [9]

商业化能力卓越，创新转型迎业绩长周期增长 [Table_CoverStock] —康哲药业(0867.HK)公司首次覆盖报告 [Table_ReportDate] 2026 年 2 月 24 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 S1500523080002 tangaijin@cindasc.com 证券研究报告 公司研究 [Table_ReportType] 公司首次覆盖报告 [Table_StockAndRank] 康哲药业(0867.HK) 投资评级 买入 上次评级 [Table_Chart] -40% -20% 0% 20% 40% 60% 80% 100% 康哲药业 恒生综合指数 资料来源：iFinD，信达证券研发中心 [Table_BaseData] 公司主要数据 | 收盘价（港元） | 15.44 | | --- | --- | | 52 周内股价波动区间(港元) | 7.15-15.45 | | 最近一月涨跌幅(％) | 13.03% | | 总股本(亿股) | 24.40 | | 流通股比例(％) | 100% | | 总市值(亿港元) | 376.66 ...

Core Viewpoint - The company, Tibet Pharmaceutical (600211), has initiated a share repurchase plan, aiming to buy back shares worth between 170 million to 200 million RMB, reflecting management's confidence in long-term value [1][2]. Stock Performance - The share repurchase plan commenced on December 18, 2025, with a maximum buyback price set at 55 RMB per share. By the end of January 2026, the company had repurchased 4,000,058 shares, accounting for 1.24% of the total share capital, with a total expenditure of approximately 178 million RMB. The highest repurchase price was 45.98 RMB per share, while the lowest was 42.66 RMB per share. This marks the company's first repurchase since 2018 [2]. Recent Events - A temporary shareholders' meeting is scheduled for February 25, 2026, with a registration date of February 10, 2026. The meeting will discuss a proposal to provide guarantees for its subsidiary, Ruizheng Gene, with a maximum liability of 120 million RMB to support its operational and R&D funding needs. Small and medium investors will have separate voting rights, and the meeting will take place at the company's office in Chengdu, Sichuan Province [3]. Industry Policy and Environment - On January 30, 2026, eight departments jointly issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)," officially announced on February 5. This plan focuses on the revitalization of ethnic medicine and the quality improvement of raw materials. As a leading Tibetan medicine company, Tibet Pharmaceutical's core products, such as Nuodikan, are expected to benefit from policy support, potentially driving business growth. The company has already invested in artificial breeding of Tibetan medicinal materials and high-standard production bases, aligning with policy directions [4]. Business Progress - The company is expanding into the innovative drug sector, having gained control over Ruizheng Gene in August 2025, which focuses on non-viral vector gene editing drugs. Additionally, in March 2025, the company invested in Chengtai Pharmaceutical, acquiring exclusive agency rights for Zorifertinib in mainland China. These initiatives aim to establish a dual-driven model of "core business + innovative business" [5].

证券代码：600211 证券简称：西藏药业 公告编号：2026-007 西藏诺迪康药业股份有限公司 关于召开2026年第一次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本公司于2026年2月5日召开第八届董事会第五次临时会议，审议通过了《董事会提议召开2026年第一次 临时股东会的议案》，公司将于2026年2月25日召开2026年第一次临时股东会，并发布了关于召开2026 年第一次临时股东会的相关通知（详见公司于2026年2月6日发布在《中国证券报》《上海证券报》《证 券时报》及上海证券交易所网站www.sse.com.cn的相关公告）。为确保公司股东充分了解本次股东会的 相关信息，现将有关事项提示公告如下： 一、召开会议的基本情况 (一)股东会类型和届次 2026年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2026年2月25日 14点30分 召开地点 ...

每经记者：王砚丹 每经编辑：陈柯名,叶峰,杜恒峰 2月10日，江淮汽车35亿元定增落地，超级牛散葛卫东与方文艳（章建平妻子）各斥资10亿元认购，并列成为第八大股东，锁定期6个月。尽管公司股价处 于历史高位、沪指徘徊于4100点，且2025年业绩预亏，但投资者仍逆势布局，显示出对江淮与华为合作车型尊界系列前景的信心。历史经验表明，牛散定 增并非稳赚，最终成效仍取决于公司基本面与市场走势。 2月10日晚，江淮汽车披露定增发行情况报告书，合计募资35亿元的再融资正式收官。 此次定增最引人瞩目的，并非募资规模本身，而是超级牛散葛卫东与方文艳（超级牛散章建平妻子）的集体重磅出手——二人分别斥资10亿元，以49.88 元/股的价格各认购2004.81万股，并列成为公司第8大股东，锁定期均为6个月。 受此消息提振，2月11日江淮汽车股价大涨。而值得注意的是，此次葛卫东重金入场，恰逢两大关键节点：江淮汽车股价处于历史高位区间，且沪指徘徊 于4100点左右的敏感位置，这一逆势加仓式的定增布局，引发市场广泛关注与讨论。 定增投资者名单堪称"豪华" 回顾江淮汽车股价走势，公司股价自2024年以来持续上涨，其股价启动甚至早于"9·2 ...

西藏诺迪康药业股份有限公司 2026 年第一次临时股东会文件 1 关于公司控股子公司提供担保的议案 各位股东： （一）锐正苏州基本情况 | 被担保人类型 法人 | | | --- | --- | | 被担保人名称 | 锐正基因（苏州）有限公司 | | 被担保人类型及上市公司 | 控股子公司 | | 持股情况 | | | 主要股东及持股比例 | 本公司控股子公司 Accuredit Therapeutics Limited 下属全资 | | | 孙公司通过 VIE 架构协议控制 | | 法定代表人 | 王永忠 | | 统一社会信用代码 | 91320594MA26MENQ3L | | 成立时间 2021 | 年 7 月 26 日 | | 注册地 | 苏州市吴中区郭巷街道吴淞江大道 111 号 3 幢 5 号楼 18 层 1814 | | 注册资本 | 人民币 100 万元 | | 公司类型 | 有限责任公司（自然人独资） | | 经营范围 | 人体基因诊断与治疗技术开发；医学研究和试验发展；技术服 务、技术开发、技术咨询、技术交流、技术转让、技术推广； | | | 技术推广服务；科技推广和应用服务 | | 项目 ...